

UNITED STATES DISTRICT COURT
SOUTHERN DISTRICT OF NEW YORK

_____X	
MARY K. JONES, Individually and on Behalf of All	: Civil Action No. 1:10-cv-03864-AKH
Others Similarly Situated,	: .
	: .
Plaintiff	: <u>CLASS ACTION</u>
	: .
vs.	: .
	: .
PFIZER INC., et al.,	: .
	: .
Defendants.	: .
_____X	

NOTICE OF PENDENCY OF CLASS ACTION

TO: ALL PERSONS WHO PURCHASED PFIZER INC. COMMON STOCK DURING THE PERIOD JANUARY 19, 2006 THROUGH JANUARY 23, 2009, INCLUSIVE

This Notice is given pursuant to Rule 23 of the Federal Rules of Civil Procedure and an order of the United States District Court for the Southern District of New York. This Notice is being sent to you because you may be a member of the Class described below. The purpose of this Notice is to inform you of the pendency of this lawsuit, how it might affect your rights and what steps you may take in relation to it. To date, no findings of fault or liability have been made as to any of the parties. Depending on the eventual outcome of this action, Class members may or may not recover money damages on the claims asserted. This Notice is not an admission by defendants or an expression of any opinion by the Court as to the merits of any of the claims asserted by plaintiffs in this litigation. Defendants have denied plaintiffs' claims and maintain that they are not liable for the injury by plaintiffs. If you do not meet the Class definition, this Notice does not apply to you and you may disregard it.

Beginning on May 11, 2010, a number of class action lawsuits were filed against Pfizer Inc. ("Pfizer") and certain Pfizer officers (collectively, the "defendants") by current or former Pfizer stockholders alleging violations of the federal securities laws. The cases were consolidated before the Honorable Alvin K. Hellerstein in the United States District Court for the Southern District of New York, and the case is presently styled *Mary K. Jones, Individually and on Behalf of All Others Similarly Situated v. Pfizer Inc., et al.*, Civil Action No. 1:10-cv-03864-AKH (the "Litigation"). By an order dated November 4, 2010, the Court appointed Stichting Philips Pensioenfonds as "lead plaintiff" pursuant to the requirements of the Private Securities Litigation Reform Act of 1995.

On March 29, 2012, the Court issued an order appointing Stichting Philips Pensioenfonds and Mary K. Jones as class representatives and certifying a "Class" that consists of:

All persons who purchased domestically or purchased on domestic exchanges Pfizer common stock between 1/19/06 and 1/23/09, inclusive, and were damaged thereby, excluding defendants and their families, directors and officers of Pfizer, and their families and affiliates.

All nominees who purchased or acquired Pfizer common stock during the period beginning on January 19, 2006 through and including January 23, 2009 for the beneficial ownership of another are requested to send this Notice to all such beneficial owners no later than ten days after receipt of this Notice. Additional copies of this Notice will be provided to such nominees upon written request sent to:

Pfizer Inc. Securities Litigation
c/o Gilardi & Co. LLC
Post Office Box 8040
San Rafael, CA 94912-8040

In the alternative, all nominees are requested to send a list of the names and addresses of such beneficial owners to Gilardi & Co. LLC at the above address no later than ten days after receipt of this Notice. Gilardi & Co. LLC will thereafter mail copies of this Notice directly to all such beneficial owners. Counsel offers to prepay the reasonable costs of preparing a list of the names and addresses of such beneficial owners or of forwarding this Notice to beneficial owners in those cases where a nominee elects to forward notice, rather than provide a list of names and addresses to Gilardi & Co. LLC.

This Notice is sent to you in the belief that you may be a Class member in this Litigation; however, mere receipt of the Notice should not be construed to indicate that a determination has been made that you are a member of the Class. To remain a Class member, you are not required to do anything. If you remain a Class member you will be bound by any judgment in this Litigation, whether it is favorable or unfavorable. If you choose to remain a Class member, you may not pursue a lawsuit on your own with regard to any of the claims assessed or issues decided in this Litigation. If you wish, you may enter an appearance through your own counsel at your own expense.

If you want to be excluded from the Class, you must state your request in writing (including your full name and address) and sign your name. If you are signing on behalf of a Class member (such as an estate, corporation or partnership), please indicate your full name and the basis of your authority. Your request for exclusion must be mailed to *Pfizer Inc. Securities Litigation*, c/o Gilardi & Co. LLC, Post Office Box 8040, San Rafael, California 94912-8040. To be effective, your

request for exclusion must comply with all of the above and be postmarked no later than **January 20, 2015**. Facsimile and email requests for exclusion are not acceptable. Requests for exclusion that do not comply with the above requirements will be invalid.

If you do properly exclude yourself from the Class, you will not be bound by any judgment in this Litigation, but you will also not be entitled to share any recovery that may result from it. If you properly request exclusion, you will be entitled to pursue any individual lawsuit, claim or remedy which you may have, at your own expense.

This Notice does not fully describe all of the claims and contentions of the parties. Complete copies of the pleadings, orders and other documents filed in this litigation may be examined and copied at any time during regular office hours at the office of the Clerk of Court, United States District Court for the Southern District of New York, 500 Pearl Street, New York, New York 10007, under Civil Action No. 1:10-cv-03864-AKH.

If you have any questions concerning the matter raised in this Notice, you may address them in writing to: Henry Rosen, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, California 92101.

If you have any corrections or changes of name or address, you may address them in writing to: *Pfizer Inc. Securities Litigation*, c/o Gilardi & Co. LLC, Post Office Box 8040, San Rafael, California 94912-8040.

PLEASE DO NOT TELEPHONE OR CONTACT THE CLERK OF THE COURT REGARDING THIS NOTICE.

DATED: November 17, 2014

BY ORDER OF THE COURT

Pfizer Inc. Securities Litigation
c/o Gilardi & Co. LLC
Post Office Box 8040
San Rafael, CA 94912-8040

Presorted First-Class Mail US Postage PAID Gilardi & Co
--

Important Legal Document.

<<Barcode>> <<ClaimID>>
<<FirstName>> <<LastName>>
<<Addr1>> <<Addr2>>
<<City>>, <<State>> <<Zip>>

PFIZER